I think an incomplete PR , with little facts and plenty "maybe". 2 months ago nobody was worried about Covid-19, thought there was and hopefully still is a plan to get listed ASAP. The PR should have clarified the status of Altucell, S1, Form10, expired IP(patents), iPO and a paragraph related to COVID19 etc. GNBT/NGIO Nasdaq listing should be priority and if successful with Covid19 and/or government funding it would reflect in the pps. Do we really want to delay the valuation, institutional participation and funding?? PPS would do much better on NASDAQ with Vaccine progress PR. I think several red flags this morning !!